Skip to main content

Advertisement

Table 1 Clinical information of patients included in the study

From: OLFM4, KNG1 and Sec24C identified by proteomics and immunohistochemistry as potential markers of early colorectal cancer stages

  Proteomics discovery set of patients IHC characterisation set of patients
Diverticular disease Adenocarcinoma Diverticular disease Adenoma Adenocarcinoma
Healthy and paired inflammatory pT1N0M0 pT2N0M0 Healthy and paired inflammatory Low grade High grade pTis pT1N0M0 pT2N0M0 pT3 pT4
Female n/male n (n total) 9/11 (20) 5/11 (16) 10/10 (20) 10/10 (20) 10/10 (20) 8/12 (20) 5/7 (12) 7/13 (20) 7/13 (20) 10/10 (20) 10/10 (20)
Age (years) median (range) 63 (51–73) 67 (52–87) 78 (61–87) 63 (41–84) 64 (55–72) 67 (48–92) 60 (45–87) 73 (54–91) 70 (55–93) 74 (54–42) 75 (39–89)
Localisation n
 Rectum 2 7 5 5 1 4 2 1
 Sigmoid 18 2 2 18 4 5 8 8 10 5 4
 Colon 2 8 5 2 8 8 2 5 6 11 13
 Cecum 4 6 3 2 1 3 2 4 2
pN stage NR NR NR NR NR NR 9 11
pM stage NR NR NR NR NR NR 2 2
Percentage of tumoral cells mdian (range) 60% (40–80) 50% (10–80)
  1. The proteomic discovery patient set (n = 56) is detailed in the left panel and the immunohistology set of patients (n = 152) is provided in the right panel. Each patient with a diverticular disease provided paired tissue samples located in two different regions: diverticular disease healthy, DH (n = 20) and inflammatory, DI (n = 20)